• en
  • de

Convergys® PT Owren

Assay for the monitoring of anticoagulation therapy and testing the integrity of the extrinsic and common pathway using the determination of the Prothrombin Time (PT). 

Convergys® PT Owren is used for the determination of the Prothrombin Time (PT). While the PT Quick assay is more widely used, the PT Owren assay has notable advantages, since it is less sensitive to interferences. Furthermore, blood (citrated or capillary) can be used as a sample for the determination of the PT.

  • Convergys® PT Owren contains thromboplastin of rabbit and a plasma fraction of bovine origin. This bovine plasma is a source of fibrinogen and factor V in the reaction and is deficient in factors II, VII and X. The fibrin clot resulting from the reaction is very strong, making the assay suitable for optical as well as mechanical detection.
  • In comparison with the more widely used PT Quick assay the PT Owren assay is less sensitive to interference by lupus antibodies (LA), platelets and an excess of citrate in the sample. Also, PT Owren is insensitive to variations in factor V and fibrinogen.
  • Using the PT Owren assay, capillary blood and citrated blood can be used as a sample in addition to plasma. It is well suited for point of care applications, since the necessary sample volume is low due to sample dilution during the assay. The results of the PT Owren assay are comparable to PT Quick results, as long as they are expressed as INR.
  • Specifications:
  • ISI value: 0.9–1.2
  • Range: up to an INR of 10
  • Sensitivity: Factors II, VII and X
  • Stability and storage conditions:
  • Shelf life: 24 months from the date of production at 2–8 °C
  • Reconstituted: 7 days at 2–8 °C
http://convergent-technologies.de/product/convergys-pt-owren/